Safety and Efficacy of Atezolizumab in Ovarian Cancer
Introduction Although the efficacy of PD-L1 blockade has been evaluated in analyses that combine pharmacologically distinct antibodies, the specific efficacy and safety of atezolizumab remain unclear. This review aimed to evaluate the efficacy and safety profile of atezolizumab specifically. Methods PubMed/MEDLINE and…
2026 463 reads 0 citations
Early View Articles
Safety and Efficacy of Atezolizumab in Ovarian Cancer
IntroductionAlthough the efficacy of PD-L1 blockade has been evaluated in analyses that combine pharmacologically distinct antibodies, the specific efficacy and safety of atezolizumab remain unclear. This review aimed to evaluate the efficacy and safety profile of atezolizumab specifically.
MethodsPubMed/MEDLINE and CENTRAL were searched (June 2026) for phase I to III trials of atezolizumab in ovarian cancer, reported in full-text English with at least 10 evaluable patients. Randomized and single-arm designs qualified. Randomized comparisons were pooled under random-effects models with Knapp-Hartung adjustment as hazard ratios for survival and risk ratios for response and safety; single-arm rates were pooled as proportions using generalized linear mixed models. Heterogeneity was assessed with I², Cochran Q, and prediction intervals, with leave-one-out sensitivity analysis. Analyses used R 4.6.0.
ResultsTwelve studies (13 reports) enrolled 3,179 patients. Atezolizumab reduced the hazard of progression (HR 0.88, 95% CI 0.83 to 0.93) and death (HR 0.86, 95% CI 0.78 to 0.96), without heterogeneity (I² = 0%), whereas objective response was unchanged (RR 0.88, 95% CI 0.52 to 1.49). Excess toxicity was immune-mediated, raising serious adverse events (RR 1.32, 95% CI 1.05 to 1.67), any-grade immune-related events (RR 1.57, 95% CI 1.12 to 2.20), and grade ≥3 immune-related events (RR 2.23, 95% CI 1.05 to 4.74).
ConclusionAtezolizumab adds a small survival benefit to a chemotherapy or bevacizumab backbone, driven by delayed progression rather than tumor regression. Offset by doubled immune toxicity and inseparable from its backbone, the effect may not justify routine use.
Keywords Atezolizumab Ovarian neoplasms Immune checkpoint inhibitors Immune-related adverse events Progression-free survival Meta-analysis All subjects
Barw Medical Journal. 2026;4(4)